Bayer teams up with biotech firm Arvinas in deal worth up to $750 million

German drugmaker Bayer has signed an alliance with Arvinas Inc to gain access to the U.S. biotech firm's experimental protein drugs and crop protection technology in a deal worth up to $750 million.